Replies to post #133493 on Biotech Values

[DewDiligence]

Gabelli analyst, Jeff Jonas…noted that investors have been a little leery about Teva because of its dependence on Copaxone. This one item accounts for about 17% of the company's sales and 20% of its profits, Jonas estimated.

Because Copaxone has a sky-high profit margin, I think Jonas is a little light on Copaxone’s share of Teva’s overall profits.

http://www.thestreet.com/_yahoo/story/11353190/1/teva-forecasts-22-billion-sales-in-2012.html